Logo image of KYMR

KYMERA THERAPEUTICS INC (KYMR) Stock Fundamental Analysis

NASDAQ:KYMR - Nasdaq - US5015751044 - Common Stock - Currency: USD

36.81  -0.61 (-1.63%)

After market: 36.81 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to KYMR. KYMR was compared to 572 industry peers in the Biotechnology industry. The financial health of KYMR is average, but there are quite some concerns on its profitability. KYMR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

KYMR had negative earnings in the past year.
KYMR had a negative operating cash flow in the past year.
In the past 5 years KYMR always reported negative net income.
In multiple years KYMR reported negative operating cash flow during the last 5 years.
KYMR Yearly Net Income VS EBIT VS OCF VS FCFKYMR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 50M -50M -100M -150M

1.2 Ratios

With an excellent Return On Assets value of -16.18%, KYMR belongs to the best of the industry, outperforming 81.88% of the companies in the same industry.
KYMR has a better Return On Equity (-18.76%) than 86.68% of its industry peers.
Industry RankSector Rank
ROA -16.18%
ROE -18.76%
ROIC N/A
ROA(3y)-22.58%
ROA(5y)-22.86%
ROE(3y)-30.2%
ROE(5y)-45.74%
ROIC(3y)N/A
ROIC(5y)N/A
KYMR Yearly ROA, ROE, ROICKYMR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KYMR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KYMR Yearly Profit, Operating, Gross MarginsKYMR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -500 -1K

More info and screens

5

2. Health

2.1 Basic Checks

KYMR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, KYMR has more shares outstanding
The number of shares outstanding for KYMR has been increased compared to 5 years ago.
KYMR has about the same debt/assets ratio as last year.
KYMR Yearly Shares OutstandingKYMR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
KYMR Yearly Total Debt VS Total AssetsKYMR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

KYMR has an Altman-Z score of 9.20. This indicates that KYMR is financially healthy and has little risk of bankruptcy at the moment.
KYMR has a better Altman-Z score (9.20) than 86.86% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that KYMR is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, KYMR is in line with its industry, outperforming 46.71% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.2
ROIC/WACCN/A
WACC9.44%
KYMR Yearly LT Debt VS Equity VS FCFKYMR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

KYMR has a Current Ratio of 8.55. This indicates that KYMR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 8.55, KYMR is in the better half of the industry, outperforming 74.78% of the companies in the same industry.
KYMR has a Quick Ratio of 8.55. This indicates that KYMR is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 8.55, KYMR is doing good in the industry, outperforming 74.78% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.55
Quick Ratio 8.55
KYMR Yearly Current Assets VS Current LiabilitesKYMR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 20.91% over the past year.
KYMR shows a strong growth in Revenue. In the last year, the Revenue has grown by 86.90%.
The Revenue has been growing by 32.18% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)20.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.89%
Revenue 1Y (TTM)86.9%
Revenue growth 3Y32.18%
Revenue growth 5YN/A
Sales Q2Q%-20.88%

3.2 Future

KYMR is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -5.28% yearly.
KYMR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 20.00% yearly.
EPS Next Y-15.36%
EPS Next 2Y-11.05%
EPS Next 3Y-12.04%
EPS Next 5Y-5.28%
Revenue Next Year-26.3%
Revenue Next 2Y-1.03%
Revenue Next 3Y-4.84%
Revenue Next 5Y20%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
KYMR Yearly Revenue VS EstimatesKYMR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
KYMR Yearly EPS VS EstimatesKYMR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KYMR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KYMR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KYMR Price Earnings VS Forward Price EarningsKYMR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KYMR Per share dataKYMR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as KYMR's earnings are expected to decrease with -12.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.05%
EPS Next 3Y-12.04%

More info and screens

0

5. Dividend

5.1 Amount

KYMR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KYMERA THERAPEUTICS INC

NASDAQ:KYMR (2/21/2025, 8:00:02 PM)

After market: 36.81 0 (0%)

36.81

-0.61 (-1.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2024-10-31/bmo
Earnings (Next)02-27 2025-02-27/amc
Inst Owners111.32%
Inst Owner Change-96.38%
Ins Owners1.3%
Ins Owner Change0.23%
Market Cap2.38B
Analysts83.85
Price Target60.13 (63.35%)
Short Float %12.04%
Short Ratio15.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.47%
Min EPS beat(2)4.15%
Max EPS beat(2)16.79%
EPS beat(4)4
Avg EPS beat(4)19.2%
Min EPS beat(4)4.15%
Max EPS beat(4)39.48%
EPS beat(8)5
Avg EPS beat(8)5.23%
EPS beat(12)5
Avg EPS beat(12)0.37%
EPS beat(16)5
Avg EPS beat(16)-48.79%
Revenue beat(2)1
Avg Revenue beat(2)17.86%
Min Revenue beat(2)-64.6%
Max Revenue beat(2)100.31%
Revenue beat(4)2
Avg Revenue beat(4)5.32%
Min Revenue beat(4)-64.6%
Max Revenue beat(4)100.31%
Revenue beat(8)3
Avg Revenue beat(8)-11.96%
Revenue beat(12)3
Avg Revenue beat(12)-18.97%
Revenue beat(16)4
Avg Revenue beat(16)-17.2%
PT rev (1m)0.18%
PT rev (3m)2.63%
EPS NQ rev (1m)-0.97%
EPS NQ rev (3m)-0.97%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.4%
Revenue NQ rev (1m)-1.2%
Revenue NQ rev (3m)-1.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 27.23
P/FCF N/A
P/OCF N/A
P/B 2.67
P/tB 2.67
EV/EBITDA N/A
EPS(TTM)-2.27
EYN/A
EPS(NY)-3.11
Fwd EYN/A
FCF(TTM)-2.29
FCFYN/A
OCF(TTM)-1.92
OCFYN/A
SpS1.35
BVpS13.79
TBVpS13.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.18%
ROE -18.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-22.58%
ROA(5y)-22.86%
ROE(3y)-30.2%
ROE(5y)-45.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 375.65%
Cap/Sales 26.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.55
Quick Ratio 8.55
Altman-Z 9.2
F-Score4
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)376.38%
Cap/Depr(5y)342.01%
Cap/Sales(3y)17.38%
Cap/Sales(5y)19.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.89%
EPS Next Y-15.36%
EPS Next 2Y-11.05%
EPS Next 3Y-12.04%
EPS Next 5Y-5.28%
Revenue 1Y (TTM)86.9%
Revenue growth 3Y32.18%
Revenue growth 5YN/A
Sales Q2Q%-20.88%
Revenue Next Year-26.3%
Revenue Next 2Y-1.03%
Revenue Next 3Y-4.84%
Revenue Next 5Y20%
EBIT growth 1Y-5.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.34%
EBIT Next 3Y-25.61%
EBIT Next 5YN/A
FCF growth 1Y4.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.89%
OCF growth 3YN/A
OCF growth 5YN/A